Clinical Policy: Erwinia Asparaginase (Erwinaze)
Reference Number: CP.PHAR.301
Effective Date: 02.01.2017
Last Review Date: 02.20
Line of Business: HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Asparaginase *Erwinia chrysanthemi* (Erwinaze®) is an asparagine specific enzyme.

FDA Approved Indication(s)
Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to *E. coli*-derived asparaginase.

Policy/Criteria
*Provider must submit documentation (including such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation® that Erwinaze is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Acute Lymphoblastic Leukemia (must meet all):
      1. Diagnosis of ALL;
      2. Prescribed by or in consultation with an oncologist or hematologist;
      3. Prescribed as a component of a multi-agent chemotherapeutic regimen;
      4. Member meets (a or b):
         a. Member has developed hypersensitivity to an *E. coli* derived asparaginase product (Elspar® - off-market) or pegaspargase (Oncaspar®);
         b. Age ≥ 65 years and Erwinaze is prescribed as combination induction therapy;
      5. Request meets one of the following (a or b):
         a. Dose should not exceed 25,000 International Units per m² administered three times per week;
         b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use *(prescriber must submit supporting evidence).*
   *Prescribed regimen must be FDA-approved or recommended by NCCN.

Approval duration: 3 months

B. Other diagnoses/indications
   1. Refer to CP.PMN.53 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).
II. Continued Therapy
   A. Acute Lymphoblastic Leukemia (must meet all):
      1. Currently receiving medication via Centene benefit, or documentation supports that
         member is currently receiving Erwinaze for a covered indication and has received this
         medication for at least 30 days;
      2. Member is responding positively to therapy;
      3. If request is for a dose increase, request meets one of the following (a or b):*
         a. New dose should not exceed 25,000 International Units per m² administered three
            times per week;
         b. New dose is supported by practice guidelines or peer-reviewed literature for the
            relevant off-label use (prescriber must submit supporting evidence).
   Approval duration: 6 months

   B. Other diagnoses/indications (must meet 1 or 2):
      1. Currently receiving medication via Centene benefit and documentation supports
         positive response to therapy.
         Approval duration: Duration of request or 6 months (whichever is less); or
      2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT
         specifically listed under section III (Diagnoses/Indications for which coverage is
         NOT authorized): HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53
         for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is
      sufficient documentation of efficacy and safety according to the off label use policy –
      HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or
      evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   ALL: acute lymphoblastic leukemia
   FDA: Food and Drug Administration

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval
   criteria. The drugs listed here may not be a formulary agent for all relevant lines of business
   and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncaspar (pegaspargase)</td>
<td>2,500 International Units/m² IM or IV, administered no more frequently than every 14 days, as part of a multi-agent chemotherapeutic regimen.</td>
<td>Varies</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.
**Appendix C: Contraindications/Boxed Warnings**

- Contraindication(s): History of 1) serious hypersensitivity reactions to Erwinaze, including anaphylaxis, 2) serious pancreatitis with prior L-asparaginase therapy, 3) serious thrombosis with prior L-asparaginase therapy, 4) serious hemorrhagic events with prior L-asparaginase therapy.
- Boxed warning(s): None reported.

**V. Dosage and Administration**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL</td>
<td>To substitute for pegaspargase: The recommended dose for each planned dose of pegaspargase is 25,000 International Units/m² administered IM or IV TIW (Monday/Wednesday/Friday) for six doses.</td>
<td>25,000 IU/m²/dose</td>
</tr>
</tbody>
</table>

**VI. Product Availability**

10,000 International Units lyophilized powder per vial

**VII. References**


**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9019</td>
<td>Injection, asparaginase, (Erwinaze), 1,000 IU</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Reviews, Revisions, and Approvals**

New policy created. 02.01.17 02.17
Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1Q18 annual review: No significant changes</td>
<td>12.11.17</td>
<td>02.18</td>
</tr>
<tr>
<td>Converted to the new template and added dosing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined FDA approved criteria and NCCN recommendations, FDA indication covers both</td>
<td></td>
<td></td>
</tr>
<tr>
<td>References reviewed and updated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1Q 2019 annual review; HIM line of business added; specialist added; per Recordati Rare Diseases, who acquired Elspar from Lundbeck in January 2013, Elspar was discontinued in 2012, there are currently no plans to reintroduce Elspar, there is no residual Elspar supply remaining on the current market, and Recordati Rare Diseases has not provided Elspar to any other territory within the global market; references reviewed and updated.</td>
<td>11.13.18</td>
<td>02.19</td>
</tr>
<tr>
<td>1Q 2020 annual review: removed HIM disclaimer for HIM NF drugs; induction therapy added per NCCN for members 65 or older; references reviewed and updated.</td>
<td>11.19.19</td>
<td>02.20</td>
</tr>
</tbody>
</table>

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a
discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.